Alexion Pharmaceuticals, Inc. (ALXN) announced that the U.S. Food and Drug Administration, or FDA, has granted the company's request for priority review of its supplemental Biologics License Application, or sBLA, for Soliris as a treatment for patients with atypical Hemolytic Uremic Syndrome, or aHUS.
If approval is granted, Alexion anticipates that Soliris would be available for U.S. patients with aHUS in the fourth quarter of 2011. In addition, the European Medicines Agency is reviewing a marketing application for Soliris as a treatment for patients with aHUS in the European Union.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.